Losordo joins Cadrenal from American Regent, Inc., where he served as Global Head Clinical Research, Development and Operations. American Regent, a Daiichi Sankyo Group Company, develops, manufactures, and supplies high quality sterile injectables for healthcare providers, clinics and hospitals across the United States and Canada. Prior to American Regent, he served as Chief Medical Officer from 2020 to 2021 of KBP Biosciences, a clinical-stage biotechnology company dedicated to research, development, and commercialization of innovative medicines for the global market. Prior to KBP, he served as Executive Vice President, Global Head of Research and Development and Chief Medical Officer of Caladrius Biosciences since 2013 and was a member of the Company’s Scientific Advisory Board from 2006 to 2013. Prior to Caladrius, he was Vice President, New Therapies Development, Regenerative Medicine, and a member of the Baxter Ventures team at Baxter International. Before beginning his career in the biotech industry in 2011, Dr. Losordo was the director of the Feinberg Cardiovascular Research Institute and the Eileen M. Foell Professor of Heart Research at Northwestern University’s School of Medicine and director of the Program in Cardiovascular Regenerative Medicine at Northwestern Memorial Hospital. Previously he was Professor of Medicine at Tufts University School of Medicine and Chief of Cardiovascular Research at St. Elizabeth’s Medical Center in Boston. He is board-certified in internal medicine, cardiovascular disease, and interventional cardiology. He received his M.D. from the University of Vermont. He has served as an associate editor of Circulation Research, the basic science journal of the American Heart Association, and serves on the editorial boards of a number of scientific journals.
